JuliaYurieKangMDMPH

PubMed

• 8 citations
  Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
  Shreya A Shah, Linus Amarikwa, Connie M Sears, Kevin D Clauss, Raneem D Rajjoub
  Ophthalmology. 2024-04-01
• 52 citations
  Teprotumumab for the treatment of chronic thyroid eye disease.
  Shoaib Ugradar, Julia Kang, Andrea L. Kossler, Erin Zimmerman, Jenna Braun
  Eye. 2021-07-09
• 3 citations
  Necrotic uveal melanoma presenting as orbital cellulitis with intraocular hemorrhage: A case report.
  Alexa L. Li, Julia Y. Kang, Duncan E. Berry, Krishna B. Patel, Andrew Hendrick
  American Journal of Ophthalmology Case Reports. 2019-09-25

Journal Articles

• Infusion Center Guidelines for Teprotumumab Infusions: Informed Consent, Safety and Management of Side Effects.  
  Kang J, Lechuga M, Braun J, Kossler A, Douglas R, Cockerham K, Journal of Infusion Nursing, 12/2021
• The Efficacy of Teprotumumab for Chronic, Progressive Thyroid Eye Disease Greater Than 9 Months  
  Connie Martin Sears, M.D, Julia Y Kang, MD, MPH, Kimberly Cockerham, MD, Andrea L Kossler, MD, Journal of the Endocrine Society, 4/2021
• Ptosis repair: external levator advancement vs. Muller’s muscle-conjunctiva resection – techniques and modifications  
  Laplant JF , Kang J Y , Cockerham KP, Plast Aesthet Res, 10/21/2020

Abstracts/Posters

• Effect and Durability of Teprotumumab on Optic Neuropathy Secondary to Thyroid Eye Disease (TED CON)
  Sears C, Kang J, Wang Y, Kossler A, Turbin R, Subramanian P, Douglas R, Cockerham K., 2021 NANOS Annual Meeting, Virtual, 2/20/2021
• Local excision of orbital metastasis from renal cell carcinoma: 3 cases including one 8-year follow-up
  Kang J, Wojno T, 2019 ARVO Annual Meeting, Vancouver, CAN, 5/2/2019
• Long-term outcomes of intrastromal ring segments for pediatric keratoconus
  Kang J, Cabot F, Vardhaman K, Yoo, S, ARVO Annual Meeting, Denver, CO, 5/5/2015